Top Menu

Revised 15.5.20: Statement on the Novel Coronavirus (2019-nCoV) and its impact on the Reliance Medical Supply Chain

29th January 2020 – Revised 15th May 2020

On 11th May 2020, the UK government outlined the first conditional steps of their COVID-19 exit strategy. At Reliance Medical we anticipate that the long-term commercial impact of this coronavirus pandemic will be felt well beyond the scheduled re-opening of schools and industry. We plan to continue the decisive social distancing measures implemented by the board which has helped to increase resilience in our supply chain, reduce the risk of transmission; resulting in staff shortages being kept to an absolute minimum, and have kept our manufacturing capabilities fully operational during this difficult period.

All staff at Reliance Medical are continuing to work at full capacity to get all orders processed and despatched as efficiently as possible. We are aware that certain couriers and postal services implementing contactless deliveries may impact on our ability to obtain signed proof of delivery confirmations. We request all customers continue to be mindful of this until delivery services return to usual practices.

We are not experiencing any stock shortages on our core first aid products. However, we continue to experience extremely high demand for PPE and infection control products. International output for PPE has increased, resulting in reduced availability and increased raw material costs. In response to these challenges Reliance Medical has investing heavily and installed additional manufacturing capability for pandemic products both in the UK and in China as part of our continued effort to secure our supply chain. The introduction of Chinese restrictions on exporting certain medical PPE products has marginally impacted on sea freight shipping schedules and we are currently experiencing a surge in air freight costs from all commercial hubs. Our dedicated COVID-19 response team are working continually to ensure we have solutions in place to meet these evolving supply chain issues.

We are extremely aware of the important role Reliance Medical products fulfil in preventing the spread of the Coronavirus. In a global healthcare emergency, the unprecedented demand for PPE unfortunately presents the opportunity for falsified medical products to enter the market. It is vital that Reliance Medical maintains our robust quality standards throughout our supply chain to ensure only effective and trusted PPE continues to fulfil our customers demand.

For further information, please contact Thomas Pear, Chief Commercial Officer, on 08456 448808.

REVISION CHANGE
29 Jan First Issue
4 Feb Board decision to extend shutdown
13 Feb Government requirement for permission to reopen + name
17 Feb Permission to reopen granted
13 Mar Extensive rewrite due to risk to UK/EU
20 Mar Notification of postal and carrier restrictions
15 May Extensive rewrite due to increased trading pressures of PPE products

29th January 2020 – Revised 20th March 2020

On 13th March 2020, the World Health Organisation declared COVID-19 to be a pandemic. At Reliance Medical, we have been closely monitoring the spread of the virus since late January and implementing decisive measures, both in our UK and Shanghai based operations, to help increase resilience in our supply chain, reduce the risk of transmission and the board has prepared plans to maintain operations despite potential staff shortages during this challenging period.

The Institute of Supply Management has reported Chinese manufacturers operating at 50% capacity. However, due to the preventative steps taken, our production has largely returned to normal and additional efforts are now being made to restore any production deficiencies from the extended closure over the Chinese New Year period.

Although the risk of the virus is still present in China, the focus of COVID-19 has now moved to Europe and the rest of the world. We are extremely aware of the important role certain Reliance Medical products fulfil in preventing the spread of the virus and we are now seeing significant increases in demand.  We have a dedicated team tasked with finding alternative sources of supply and have invested heavily to increase production capacities to return these product lines to stock with minimal fluctuations in raw material costs and delay.  Despite shortages in specific categories, it is vital to provide assurance that our core first aid lines remain in stock.  We are experiencing delays associated with air and sea freight but do not expect any significant issues due to organisations stock holdings in the UK.

While we are working to get all orders processed and despatched as efficiently as possible, we are receiving notifications from couriers and postal services implementing contactless deliveries.  This may impact on our ability to obtain signed proof of delivery confirmations and we request all customers to be mindful of this over the coming weeks.

This is a rapidly evolving situation and we continue to closely monitor the global impact of the COVID-19 pandemic.  We will update this statement in the event of any changing circumstance.

For further information, please contact Thomas Pear, Chief Commercial Officer, on 08456 448808.

 

REVISION CHANGE
29 Jan First Issue
4 Feb Board decision to extend shutdown
13 Feb Government requirement for permission to reopen + name
17 Feb Permission to reopen granted
13 Mar Extensive rewrite due to risk to UK/EU
20 Mar Notification of postal and carrier restrictions

 


Revised 18th March 2020

On 13th March 2020, the World Health Organisation declared COVID-19 to be a pandemic. At Reliance Medical, we have been closely monitoring the spread of the virus since late January and implementing decisive measures, both in our UK and Shanghai based operations, to help increase resilience in our supply chain, reduce the risk of transmission and the board has prepared plans to maintain operations despite potential staff shortages during this challenging period.

The Institute of Supply Management has reported Chinese manufacturers operating at 50% capacity. However, due to the preventative steps taken, our production has largely returned to normal and additional efforts are now being made to restore any production deficiencies from the extended closure over the Chinese New Year period. 

Although the risk of the virus is still present in China, the focus of COVID-19 has now moved to Europe and the rest of the world. We are extremely aware of the important role certain Reliance Medical products fulfil in preventing the spread of the virus and we are now seeing significant increases in demand.  We have a dedicated team tasked with finding alternative sources of supply and have invested heavily to increase production capacities to return these product lines to stock with minimal fluctuations in raw material costs and delay.  Despite shortages in specific categories, it is vital to provide assurance that our core first aid lines remain in stock.  We are experiencing delays associated with air and sea freight but do not expect any significant issues due to organisations stock holdings in the UK.

This is a rapidly evolving situation and we continue to closely monitor the global impact of the COVID-19 pandemic.  We will update this statement in the event of any changing circumstance.

For further information, please contact Thomas Pear, Chief Commercial Officer, on 08456 448808.

 

 


29th January 2020 – Revised 17th February 2020

During this Chinese New Year period, we have been watching with concern the developments around the 2019-nCoV Coronavirus in China. The health and well being of our colleagues at our Chinese subsidiary based in Shanghai has been at the forefront of our minds.

The New Year period is typically a time of celebration during which most businesses close and people travel across China to reunite with family. As such, Reliance Medical closed on 22nd January and had been planning to return on 3rd February which was extended to 10th February following a board decision. Fortunately, to date, none of our team have contracted the virus and we have confirmed that none travelled to the Hubei province during their holidays.

Since our decision to extend our factory shutdown, it has been announced by the local government in Shanghai that all businesses must obtain approval to reopen, we have been granted permission to reopen on 17th February and will be doing so in a limited capacity with immediate affect.

As a manufacturer of medical products, we have in place strict controls to reduce the risk of contamination and spread of disease; in preparation for the factories return to work we have re-evaluated these measures and taken steps to further reduce the risk to our team and our production.

We have evaluated our supply chain and established that the majority of our raw materials are sourced from the Shanghai area, with only a single supplier in the Hubei Province. We do not currently anticipate any difficulty from this but nevertheless are speaking with all critical suppliers to ensure continuity of supply.

At this moment in time we consider the impact on our supply chain to be negligible and fully expect our stock holdings in the UK to be sufficient to account for the minor dip in production as a result of the delayed return to work.

This is a rapidly changing situation and we continue to closely monitor events. We will update this statement in the event of any changing circumstance.

For further information, please contact Thomas Pear, Chief Commercial Officer, on 08456 448808.